Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of emactuzumab versus placebo in tenosynovial giant cell tumour
2021-001716-29Phase 3Completed
- Sponsor
- SynOx Therapeutics
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in tenosynovial giant cell tumor (TGCT) and Giant Cell Tumor of Bone (GCTB) comparing Emactuzumab with Placebo (2 arms). Primary endpoint: Objective Response Rate at 6 months. Started Mar 2022; status: completed.
02
Drugs
emactuzumab
03
Conditions
tenosynovial giant cell tumor (TGCT)Giant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on 2021-001716-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001716-29.